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Background: Cytomegalovirus infection and disease are 
potential risk factors for acute allograft rejection in renal 
transplant recipients. 
Methods: From October 1994 to July 1997, 477 con- 
secutive renal allograft recipients (397 first transplants 
and 80 retransplants) were included in the study. 
Cytomegalovirus infection (cytomegalovirus pp65 
antigen in leukocytes) and disease (infection and clinical 
symptoms or signs of disease) were examined pro- 
spectively for 3 months. No cytomegalovirus prophylaxis 
was given, and cytomegalovirus disease was treated 
with i.v. ganciclovir. The retransplantation of 4 patients 
transplanted twice during the study and 22 patients 
receiving kidneys from HLA-identical siblings were 
excluded from statistical analysis. Rejections were 
evaluated clinically (277 (61%)) and 173 (38%) also had 
a biopsy verified rejection. 
Results: Cytomegalovirus infection occurred in 64% of 
the patients and 24% experienced cytomegalovirus 
disease. In a multiple time-dependent Cox analysis 
independent significant predictors for clinical acute 
rejections were cytomegalovirus infection, RR=1.6 
(1.1-2.5, p=O.O2), cytomegalovirus disease, RR=2.5 
(1.2-5.l,p=O.O1). Among 173 patients with biopsy veri- 
fied rejection 72% of the patients had tubulointerstitial 
rejection whereas 28% had a vascular rejection. 
cytomegalovirus disease, but not cytomegalovirus in- 
fection was a predictor of tubulointerstitial rejection, 
RR=3.1 (l.l-9.3,p=O.O4). 
Conclusion: Cytomegalovirus infection and disease are 
independent risk factors for clinically acute rejection 
in kidney risk factor for biopsy verified acute tubulo- 
interstitial rejection in kidney allograft recipients. 
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Introduction: Cytomegalovirus (CMV) disease occurs 
frequently after solid organ transplantation and has 
been associated with decreased patient and allograft 
survival. IVIg have been used in organ transplantation 
in combination with antiviral agents to treat established 
CMV disease. However, only limited data in heart trans- 
planted patients with secondary hypogammaglobu- 
linemia exist. 
Patients and Methods: We assessed the overall pre- 
valence of significant hypogammaglobulinemia in the 
post-transplantation period after heart transplantation. 
We present data on 5 heart transplanted patients with 
recurrent CMV infection, four of whom developed 
gastrointestinal disease. One of the patients associated 
acute graft rejection. An immunologic evaluation 
showed hypogammaglobulinemia (mean IgG levels: 
323+40 mg/dl (n.v. 700-1600 mg/dl)) in all the patients. 
The mean absolute number of CD4+ T-cells and 
B lymphocyte counts were 429?233 and 67240 cells/ 
mm3, respectively. IVIg (Flebogamma@) 200-400 mg/kg 
every 21 days plus antiviral treatment with gancyclovir 
was administered to the patients. After treatment the 
patients were followed-up for a mean period of 12 
months. 
Results: IVIg treatment, in combination with antiviral 
therapy, proved able to control CMV disease. There was 
a favorable clinical response and the patients became 
free of gastrointestinal symptoms. Detection of CMV 
antigens was negative after treatment. 
Conclusions: Even if our survey was limited to only 
five cases, the results indicated that addition of IVIg to 
antiviral chemotherapy might improve outcome in heart 
transplanted patients with CMV disease and hypo- 
gammaglobulinaemia. 
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Objective: To assess if keeping a previously placed IC is 
associated with an increase in morbidity in patients 
undergoing APSCT. 
Methods: We reviewed all pts who underwent APSCT 
with an IC in place from 3/97 to l/02. We compared these 
pts with a control group (no IC in place) that was 
matched by disease, age, and sex. 
Results: 43 pts (IC group) were matched with 43 
controls (no IC). In both groups the age (mean 40 years 
old), the sex distribution (58% females), and the 
duration of neutropenia (mean 8 days) were the same. 
Underlying malignancies included multiple myeloma 
(14 and 12) lymphoma (22 and 24) leukemia (3 and 3) 
and others (4 and 4) in the IC and no IC groups, 
respectively. Antibacterial and antifungal prophylaxis 
were used in 18 and 23 pts in the IC group vs 10 and 17 
pts in the no IC group (P=NS). The IC were used in 20 
of 43 pts within the 60 days of transplantation The 
endpoints shown in the table were used as markers of 
morbidity: 
